



Forbion.
Impacting the future of medicine

FORBION

Intro



July 2024



FORBION: A LEADING LIFE SCIENCES INVESTMENT FIRM



Stable and experienced team



Strong track record of successful exits

Forbion.

Impacting the future of medicine

€3bn

assets under management



25+%
net IRR



>1.3M
patients impacted



18
product launches



European focus, with transatlantic play



Institutional investor base, with impact focus

TRACK RECORD


Non-exhaustive sample of exits

Pharma M&A	 Asset (NM26) acquisition by \$1.25Bn May 2024	 Acquired by UP TO \$1.75Bn May 2024	 Acquired by UP TO \$1.4Bn January 2024	 Acquired by UP TO \$1.07Bn August 2023	 Acquired by UP TO \$1.925Bn July 2023	 Acquired by \$1.2Bn May 2023	 Acquired by UP TO \$1.5Bn December 2021
	 Acquired by Undisclosed (upfront €205Mn) November 2021	 Acquired by Undisclosed (upfront €380Mn) September 2020	 Acquired by UP TO \$1.5Bn August 2020	 Acquired by UP TO \$1.4Bn November 2019	 Acquired by UP TO \$575Mn June 2018	 Acquired by UP TO €905Mn March 2018	 Acquired by UP TO €464Mn August 2017
IPO	in portfolio IPO \$625.79Mn* November 2023	in portfolio IPO \$1.79Bn* November 2022	in portfolio IPO \$2.51Bn* September 2020	in portfolio IPO \$412.53Mn* July 2018	Realized IPO 10.9x MOIC July 2014	Realized IPO 2.3x MOIC February 2014	Realized IPO 5.4x MOIC June 2013

* Market Capitalization on May 17, 2024

FORBION PLATFORM

Synergistic platform of funds - each with a specific purpose - serving a defined market



SCALE, SYNERGY, SUCCESSION

Investment Team



Sander Slootweg,
MSc
Managing Partner



Geert-Jan Mulder,
MD
Managing Partner



Martien van Osch,
MSc
Managing Partner



Marco Boorsma, PhD
General Partner



Nanna Lüneborg,
PhD
General Partner



Dirk Kersten, MSc
General Partner



Rogier Rooswinkel,
PhD
General Partner



Wouter Joustra, MSc
General Partner



Jasper Bos, PhD
General Partner



Holger Reithinger,
PhD
General Partner



Vincent van Houten,
MSc
CFO



Robbert van de Griendt, MSc,
General Partner
IR/Impact



Dmitrij Hristodorov,
PhD
General Partner



Josh Brumm, BA
General Partner



Mathias Vinther, PhD
Principal



Audrey Cacaly, MSc
Principal



Antoine Boulanger,
PhD
Principal



Vanessa Carle, PhD
Senior Associate



Marc-Olivier
Turgeon, PhD
Senior Associate



Tim Lohoff, PhD
Senior Associate



Alice Vickers, PhD
Associate



Anne Marije van
Harten, PhD
Analyst



Melanie de Almeida,
PhD
Analyst



Gilles van Tienderen,
PhD
Analyst



Daniel Bode, PhD
Analyst

Operating & Venture Partners



Carlo Incerti
MD
Operating Partner



John Kastelein
MD, PhD, FESC
Operating Partner



John Montana
PhD, MRSA
Operating Partner



Patrick Vink
MD
Venture Partner



Peter Høngaard
Andersen
Operating Partner



Sander van
Deventer, MD, PhD
Operating Partner



Thomas Rasmussen
Operating Partner



Rory Gummerson
Operating Partner



Matt Cooper
PhD
Venture Partner



John Ford, PhD
Venture Partner



Philip Astley-
Sparke, FSA
Venture Partner



Michael Hayden PhD
Venture Partner



Ton Logtenberg PhD
Venture Partner



James Rush, PhD
Venture Partner



Patrick Round, MD
Venture Partner

Advisors

Advisors



Alexander
Eggermont, MD,
PhD
Advisor



Frank G. Holz, Prof
Advisor



John Ford, PhD
Advisor



Prof Simon J Clark
Advisor



Scott Friedman,
MD
Advisor



William Sandborn,
MD
Advisor



Yigal M. Pinto,
MD, PhD
Advisor